+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Venous Leg Ulcers Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830093
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 57 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Aurealis Pharma AG
  • CytoTools AG
  • Daval International Ltd
  • FirstString Research Inc
  • Hypo-Stream Ltd
  • Ilkos Therapeutics Inc
  • MORE
High levels of pipeline activity are being observed in Venous Leg Ulcers treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Aurealis Pharma AG, CardioVascular BioTherapeutics Inc, CytoTools AG, Daval International Ltd, FirstString Research Inc and others.

A Significant contribution to the Venous Leg Ulcers pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Venous Leg Ulcers pipeline included 11 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Venous Leg Ulcers condition and increased access to investments is encouraging growth of Venous Leg Ulcers drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Venous Leg Ulcers drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Venous Leg Ulcers therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Venous Leg Ulcers pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Venous Leg Ulcers. Further, orphan drug status, fast track designation, grants awarded and other special status for Venous Leg Ulcers pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Venous Leg Ulcers pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Venous Leg Ulcers Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Venous Leg Ulcers drugs
  • Late phase: Phase 3 and in-approval Venous Leg Ulcers drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Venous Leg Ulcers therapeutic treatment activities
Details for each Venous Leg Ulcers drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Venous Leg Ulcers therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aurealis Pharma AG
  • CytoTools AG
  • Daval International Ltd
  • FirstString Research Inc
  • Hypo-Stream Ltd
  • Ilkos Therapeutics Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Venous Leg Ulcers- Disease Overview
2.2 Venous Leg Ulcers- Pipeline Snapshot
2.3 Venous Leg Ulcers- Pipeline Drugs by Phase
2.4 Venous Leg Ulcers- Pipeline Drugs by Company
2.5 Venous Leg Ulcers- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 Aurealis Pharma AG Venous Leg Ulcers Drug Pipeline, H2- 2019
3.2 CardioVascular BioTherapeutics Inc Venous Leg Ulcers Drug Pipeline, H2- 2019
3.3 CytoTools AG Venous Leg Ulcers Drug Pipeline, H2- 2019
3.4 Daval International Ltd Venous Leg Ulcers Drug Pipeline, H2- 2019
3.5 FirstString Research Inc Venous Leg Ulcers Drug Pipeline, H2- 2019
3.6 Hypo-Stream Ltd Venous Leg Ulcers Drug Pipeline, H2- 2019
3.7 Ilkos Therapeutics Inc Venous Leg Ulcers Drug Pipeline, H2- 2019
3.8 MallInckrodt Plc Venous Leg Ulcers Drug Pipeline, H2- 2019
3.9 MediWound Ltd Venous Leg Ulcers Drug Pipeline, H2- 2019
3.10 Promore Pharma AB Venous Leg Ulcers Drug Pipeline, H2- 2019
3.11 QBiotics Ltd Venous Leg Ulcers Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Venous Leg Ulcers- Phase 1 Drug Details
4.2 Venous Leg Ulcers- Phase 1 Drug Overview
4.3 Venous Leg Ulcers- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Venous Leg Ulcers- Phase 2 Drug Details
5.2 Venous Leg Ulcers- Phase 2 Drug Overview
5.3 Venous Leg Ulcers- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Venous Leg Ulcers- Phase 3 Drug Details
6.2 Venous Leg Ulcers- Phase 3 Drug Overview
6.3 Venous Leg Ulcers- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Venous Leg Ulcers- Pre-clinical Phase Drug Details
7.2 Venous Leg Ulcers- Pre-clinical Phase Drug Overview
7.3 Venous Leg Ulcers- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aurealis Pharma AG
  • CardioVascular BioTherapeutics Inc
  • CytoTools AG
  • Daval International Ltd
  • FirstString Research Inc
  • Hypo-Stream Ltd
  • Ilkos Therapeutics Inc
  • MallInckrodt Plc
  • MediWound Ltd
  • Promore Pharma AB
  • QBiotics Ltd
Note: Product cover images may vary from those shown
Adroll
adroll